Free Trial

BMO Capital Markets' Rating of Regeneron Pharmaceuticals on 9/9/2026

On September 9, 2026, BMO Capital Markets updated its outlook on Regeneron Pharmaceuticals (NASDAQ:REGN) with the action "Boost Price Target", setting a price target of $920.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BMO Capital Markets

DateCompanyAction
10/16/2026
Netflix, Inc. stock logo
NFLX
Netflix
Set Price Target
10/15/2026
The Progressive Corporation stock logo
PGR
Progressive
Reiterated Rating
10/15/2026
Workday, Inc. stock logo
WDAY
Workday
Reiterated Rating
10/15/2026
The Progressive Corporation stock logo
PGR
Progressive
Set Price Target
10/15/2026
Visa Inc. stock logo
V
Visa
Reiterated Rating
10/15/2026
Mastercard Incorporated stock logo
MA
Mastercard
Reiterated Rating
More Ratings From BMO Capital Markets